Back to top

Image: Bigstock

Editas Medicine (EDIT) Catches Eye: Stock Jumps 9%

Read MoreHide Full Article

Editas Medicine, Inc. (EDIT - Free Report) was a big mover last session, as the company saw its shares rise 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $14.88–$26.54 in the past one-month time frame, witnessed a sharp increase yesterday.

The company has seen one negative estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Editas Medicine currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.  

Editas Medicine, Inc. Price


A better-ranked stock in the Medical - Biomedical and Genetics industry is CorMedix Inc (CRMD - Free Report) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


CorMedix Inc (CRMD) - free report >>

Editas Medicine, Inc. (EDIT) - free report >>

Published in